Product Description
MK-0533 is a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus. In comparison with PPAR_ full agonists, MK-0533 displayed diminished maximal activity (partial agonism) in cell-based transcription activation assays and attenuated gene signatures in adipose tissue.Ê (Sourced from: https://drugs.ncats.io/drug/J17152066B)
Mechanisms of Action: PPAR-g Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes|General Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2006-002090-47 |
12 week study of MK - 0533 in patients with T2DM | P2 |
Terminated |
General Diabetes |
2007-10-19 |
2022-03-12 |
Treatments |
|
NCT00543959 |
MK0533-005 | P2 |
Terminated |
Type 2 Diabetes |
2007-08-01 |
2022-05-04 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|